SCHEMBL22380433

SCHEMBL22380433

CC(C)(C)OC(=O)N[C@@]1(CO)C[C@H]1C(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.40
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 1/20 0.38
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
DPP8 Q6V1X1 2/20 0.32
DPP9 Q86TI2 2/20 0.32
CACNA1H O95180 1/20 0.32
CTSL P07711 1/20 0.32
CTSK P43235 2/20 0.32
GAA P10253 1/20 0.32
GFER P55789 1/20 0.32
EPHX1 P07099 1/20 0.31
CTSS P25774 1/20 0.31
HSD11B1 P28845 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13742611 0.80 MEN1 (0.42) APLNRMEN1KMT2AMAPK1HDAC4
SCHEMBL5428985 0.80 MEN1 (0.42) APLNRMEN1KMT2AMAPK1HDAC4
SCHEMBL8089082 0.80 MEN1 (0.42) APLNRMEN1KMT2AMAPK1HDAC4
SCHEMBL13360951 0.78 KMT2A (0.41) APLNRMEN1KMT2AMAPK1HDAC4
SCHEMBL22644339 0.77 APLNR (0.40) APLNRMEN1KMT2AMAPK1HDAC4
SCHEMBL22363005 0.76
SCHEMBL8088306 0.76 KMT2A (0.39) APLNRMEN1KMT2AMAPK1HDAC4
SCHEMBL634842 0.75 KMT2A (0.38) APLNRMEN1KMT2AMAPK1HDAC4
SCHEMBL20107170 0.75 KMT2A (0.38) APLNRMEN1KMT2AMAPK1HDAC4
SCHEMBL3345289 0.75 KMT2A (0.38) APLNRMEN1KMT2AMAPK1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
US-20250376468-A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
EP-4499636-A2 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023230542-A2 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
US-20200268730-A1 AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES JANSSEN PHARMACEUTICA NV (BE) 2020-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376468-A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM5, TRPM4 APLNR 1181/4885MEN1 1479/4885KMT2A 3169/4885
US-20200268730-A1 AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES HDGF, FABP1, NR1H4 APLNR 625/4885MEN1 4681/4885KMT2A 2809/4885
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 APLNR 2139/4885MEN1 1744/4885KMT2A 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.